CNSP icon

CNS Pharmaceuticals
CNSP

8 hedge funds and large institutions have $222K invested in CNS Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 7 closing their positions.

Upgrade to unlock
New
Increased
Maintained
Reduced
Closed

more ownership

Funds ownership: →

less funds holding

Funds holding: →

less first-time investments, than exits

New positions opened: | Existing positions closed:

less capital invested

Capital invested by funds: $ → $
Holders
8
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$126K
2
+$70.6K
3
+$252
4
Citigroup
Citigroup
New York
+$18

Top Sellers

1
-$335K
2
-$19K
3
-$14.7K
4
TSS
Two Sigma Securities
New York
-$12.9K
5
HF
HRT Financial
New York
-$8K
Name Holding Trade Value Shares
Change 		Change in
Stake
DS
1
DRW Securities
Illinois
$126K
UBS Group
2
UBS Group
Switzerland
$94.7K
Morgan Stanley
3
Morgan Stanley
New York
$252
BC
4
Barrett & Company
Rhode Island
$72
Bank of America
5
Bank of America
North Carolina
$36
MCM
6
MAI Capital Management
Ohio
$27
Citigroup
7
Citigroup
New York
$18
DB
8
Danske Bank
Denmark
$9
AC
9
Armistice Capital
New York
–
VF
10
Virtu Financial
New York
–
Geode Capital Management
11
Geode Capital Management
Massachusetts
–
TSS
12
Two Sigma Securities
New York
–
HF
13
HRT Financial
New York
–
TRCT
14
Tower Research Capital (TRC)
New York
–
SS
15
SBI Securities
Japan
–